Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease.
NASH
biopsy
cardiovascular
end-stage liver disease
iron overload
non-alcoholic fatty liver disease
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
25
02
2020
revised:
29
04
2020
accepted:
01
05
2020
pubmed:
8
5
2020
medline:
22
6
2021
entrez:
8
5
2020
Statut:
ppublish
Résumé
Approximately one-third of patients with non-alcoholic fatty liver disease (NAFLD) show signs of mild-to-moderate iron overload. The impact of histological iron deposition on the clinical course of patients with NAFLD has not been established. For this retrospective study, 299 consecutive patients with biopsy-proven NAFLD and a mean follow-up of 8.4 (±4.1; range: 0.3-18.0) years were allocated to one of four groups according to presence of hepatic iron in the reticuloendothelial system (RES) and/or hepatocytes (HC): 156 subjects (52%) showed no stainable iron (NONE), 58 (19%) exclusively reticuloendothelial (xRES), 19 (6%) exclusively hepatocellular (xHC) and 66 (22%) showed a mixed (HC/RES) pattern of iron deposition. A long-term analysis for overall survival, hepatic, cardiovascular or extrahepatic-malignant events was conducted. Based on multivariate Cox proportional hazards models any reticuloendothelial iron was associated with fatal and non-fatal hepatic events. Specifically, xRES showed a cause-specific hazard ratio (csHR) of 2.4 (95%-CI, 1.0-5.8; P = .048) for hepatic as well as cardiovascular fatal and non-fatal events combined (csHR 3.2; 95%-CI, 1.2-8.2; P = .015). Furthermore, the mixed HC/RES iron pattern showed a higher rate of combined hepatic fatal and non-fatal events (csHR 3.6; 95%-CI, 1.4-9.5; P = .010), while xHC iron deposition was not associated with any defined events. The presence of reticuloendothelial-accentuated hepatic iron distribution patterns is associated with detrimental long-term outcomes reflected in a higher rate of both liver-related and cardiovascular fatal and non-fatal events.
Sections du résumé
BACKGROUND & AIMS
Approximately one-third of patients with non-alcoholic fatty liver disease (NAFLD) show signs of mild-to-moderate iron overload. The impact of histological iron deposition on the clinical course of patients with NAFLD has not been established.
METHODS & RESULTS
For this retrospective study, 299 consecutive patients with biopsy-proven NAFLD and a mean follow-up of 8.4 (±4.1; range: 0.3-18.0) years were allocated to one of four groups according to presence of hepatic iron in the reticuloendothelial system (RES) and/or hepatocytes (HC): 156 subjects (52%) showed no stainable iron (NONE), 58 (19%) exclusively reticuloendothelial (xRES), 19 (6%) exclusively hepatocellular (xHC) and 66 (22%) showed a mixed (HC/RES) pattern of iron deposition. A long-term analysis for overall survival, hepatic, cardiovascular or extrahepatic-malignant events was conducted. Based on multivariate Cox proportional hazards models any reticuloendothelial iron was associated with fatal and non-fatal hepatic events. Specifically, xRES showed a cause-specific hazard ratio (csHR) of 2.4 (95%-CI, 1.0-5.8; P = .048) for hepatic as well as cardiovascular fatal and non-fatal events combined (csHR 3.2; 95%-CI, 1.2-8.2; P = .015). Furthermore, the mixed HC/RES iron pattern showed a higher rate of combined hepatic fatal and non-fatal events (csHR 3.6; 95%-CI, 1.4-9.5; P = .010), while xHC iron deposition was not associated with any defined events.
CONCLUSIONS
The presence of reticuloendothelial-accentuated hepatic iron distribution patterns is associated with detrimental long-term outcomes reflected in a higher rate of both liver-related and cardiovascular fatal and non-fatal events.
Identifiants
pubmed: 32378295
doi: 10.1111/liv.14503
pmc: PMC7496452
doi:
Substances chimiques
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1872-1882Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Circulation. 2004 Jul 13;110(2):227-39
pubmed: 15249516
Hepatology. 1999 Dec;30(6):1356-62
pubmed: 10573511
Haematologica. 2017 Dec;102(12):1972-1984
pubmed: 29101207
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
Liver Int. 2016 Nov;36(11):1688-1695
pubmed: 27064133
Hepatology. 2013 May;57(5):1806-13
pubmed: 23325576
Curr Top Dev Biol. 2008;82:141-67
pubmed: 18282520
Stat Med. 1990 Jul;9(7):811-8
pubmed: 2218183
World J Gastroenterol. 2014 Mar 21;20(11):3002-10
pubmed: 24659891
Nutrients. 2014 Sep 11;6(9):3587-600
pubmed: 25215659
Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2
pubmed: 29705261
J Res Med Sci. 2014 Feb;19(2):164-74
pubmed: 24778671
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Gastroenterology. 2006 Sep;131(3):788-96
pubmed: 16952548
Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60
pubmed: 21440669
Liver Int. 2020 Aug;40(8):1872-1882
pubmed: 32378295
J Clin Med. 2018 Dec 17;7(12):
pubmed: 30562976
J Hepatol. 2017 Nov 2;:
pubmed: 29150142
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Am J Clin Nutr. 2008 May;87(5):1374-83
pubmed: 18469261
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Minerva Endocrinol. 2017 Jun;42(2):173-183
pubmed: 27834478
Gastroenterology. 2018 Aug;155(2):443-457.e17
pubmed: 29733831
Aliment Pharmacol Ther. 2009 Jan;29(2):183-92
pubmed: 18945251
Br J Haematol. 2018 May;181(3):331-340
pubmed: 29672840
Gastroenterology. 2009 Oct;137(4):1301-9
pubmed: 19622361
Crit Rev Food Sci Nutr. 2019;59(3):443-449
pubmed: 28886251
Liver Int. 2019 Jul;39(7):1325-1334
pubmed: 30851216
Hepatol Res. 2018 Feb;48(3):E30-E41
pubmed: 28593739
Hepatology. 2012 Jan;55(1):77-85
pubmed: 21953442
Hepatology. 2011 Feb;53(2):448-57
pubmed: 21274866
J Hepatol. 1997 Nov;27(5):773-9
pubmed: 9382962
Hepatology. 2012 Nov;56(5):1751-9
pubmed: 22707395
Semin Liver Dis. 2011 Aug;31(3):260-71
pubmed: 21901656
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Aliment Pharmacol Ther. 2013 Apr;37(7):720-9
pubmed: 23441892